[e-drug] SIAPS launches new PViMS tool for improved pharmacovigilance

e-drug
1

E-DRUG: SIAPS launches new PViMS tool for improved pharmacovigilance
-------------------------------------------------------------------------------------------------

At the 46th Union World Conference on Lung Health
<http://capetown.worldlunghealth.org/&gt;
the USAID-funded SIAPS Program launched a new tool to improve pharmacovigilance in low- and middle-income countries.

Although all medicines undergo rigorous clinical testing prior
to being made publicly available, continuing to monitor the safety and
effectiveness of medicines in real world settings, also referred to as
pharmacovigilance, is critically important to ensure that medicines can
be used over a prolonged period of time, in conjunction with other
medicines, among new patient populations, and in patients with multiple
illnesses.

Low- and middle-income countries however often lack the resources,
capacity, and systems required to effectively implement pharmacovigilance
activities and rely heavily on passive reporting methods which can
underestimate potential medicines use issues.

One common barrier to effective pharmacovigilance is the lack of available
data collection and analysis tools for active pharmacovigilance. To help
address this challenge, SIAPS developed a web-based application to
streamline and simplify the data collection and analysis process, known as
the Pharmacovigilance Monitoring System (PViMS)

<http://siapsprogram.org/wp-content/uploads/2016/01/PViMS-Brochurev4-nobleed.pdf&gt;
.
The only free software of its kind customized for use in low resource
settings, PViMS helps clinicians, regulatory authorities, program managers,
and other implementing partners collect, analyze, and monitor adverse
reactions associated with the use of medicines, including those used to
treat tuberculosis. In addition to improving documentation and reporting of
adverse drug events, PViMS can also be used to alert program managers to
potential problems by flagging medicines use issues for further evaluation.

With PViMS, regulatory authorities, program managers, physicians, and
pharmacists have a tool which helps to ensure that the medicines they
provide to mothers and their children are not only safe and effective, but
also help them attain the best possible health outcomes.

*For more information on PViMS, read our brochure

<http://siapsprogram.org/wp-content/uploads/2016/01/PViMS-Brochurev4-nobleed.pdf&gt;\*